2021 American Transplant Congress
Simulation Model for Cytomegalovirus Matching in Deceased Donor Kidney Allocation System in the U.S.
*Purpose: The prevalence of positive and negative cytomegalovirus (CMV) serology among transplant recipients and donors are approximately 60-65% and 30-35%, respectively. CMV mismatch, donor-positive/recipient-negative status…2021 American Transplant Congress
Cytomegalovirus Nephritis: Epidemiology and Outcomes of an Uncommon Diagnosis
Division of Nephrology, University of Wisconsin-Madison, Madison, WI
*Purpose: Cytomegalovirus (CMV) nephritis is an uncommon end-organ manifestation of CMV disease. Due to this, associated outcomes have not been completely elucidated.*Methods: This was a…2021 American Transplant Congress
Excellent Outcomes of Kidney Transplantation from Hepatitis C Infected Donors
UVA Health System, University of Virginia, Charlottesville, VA
*Purpose: Utilization of Hepatitis C viremic (HCV D+) kidney donors in HCV naïve recipients has increased in the United States. While there are shorter waiting…2021 American Transplant Congress
Economic and Clinical Benefit of Cmv Matching in Kidney Transplantation
*Purpose: Recently, kidney transplant (KTx) centers in Oregon collaborated to preferentially allocate cytomegalovirus-seronegative (CMV D-) kidneys to seronegative recipients (CMV R-), successfully reducing high-risk CMV…2021 American Transplant Congress
Changes in Cytomegalovirus Specific T Cell Immunity With Immunomodulation in Serodiscordant High Risk Transplant Recipients
Virginia Commonwealth University Health, Richmond, VA
*Purpose: Cytomegalovirus (CMV) infections cause significant morbidity and mortality among all solid organ transplant recipients. CMV discordant (D+/R-) recipients are at higher risk of developing…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…2021 American Transplant Congress
Ganciclovir Therapeutic Drug Monitoring in Obese Adults Patients – Opportunity for Clinical Utility
*Purpose: Ganciclovir (GCV) is the drug of choice for the treatment of cytomegalovirus (CMV) infection; optimal dosing of GCV in the obese patient population is…2021 American Transplant Congress
Cytomegalovirus (CMV) D+/R- Serostatus is Independently Associated with Mortality and Graft Loss After Liver Transplantation (LTx)
Internal Medicine, University of Washington Medical Center, Seattle, WA
*Purpose: It is unknown if donor or recipient (D/R) CMV serostatus, in the era of CMV prophylactic and pre-emptive strategies, remains associated with clinical outcomes…2021 American Transplant Congress
Outcomes Among CMV Mismatched and Highly Sensitized Kidney Transplant Recipients Who Develop Leukopenia or Neutropenia
*Purpose: Kidney transplant recipients (KTRs) who receive antiproliferative agents for immunosuppression and valganciclovir for CMV prophylaxis are at high risk of developing leukopenia and neutropenia.…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 33
- Next Page »